Signal Peptide Website
Search my Protein
Advanced Search
Database Search
References
Hints
Links
Imprint
Signal Peptide Database - Drosophila melanogaster
Entry Details
ID
29727
Source Database
UniProtKB/Swiss-Prot
UniProtKB/Swiss-Prot Accession Number
P16621 (Created: 1990-08-01 Updated: 2009-01-20)
UniProtKB/Swiss-Prot Entry Name
LAR_DROME
Protein Name
Tyrosine-protein phosphatase Lar
Gene
Lar
Organism Scientific
Drosophila melanogaster
Organism Common
Fruit fly
Lineage
Eukaryota
Metazoa
Arthropoda
Hexapoda
Insecta
Pterygota
Neoptera
Endopterygota
Diptera
Brachycera
Muscomorpha
Ephydroidea
Drosophilidae
Drosophila
Sophophora
Protein Length [aa]
2029
Protein Mass [Da]
229056
Features
Type
Description
Status
Start
End
signal peptide
1
32
chain
Tyrosine-protein phosphatase Lar
33
2029
disulfide bond
potential
57
111
disulfide bond
potential
161
209
disulfide bond
potential
256
301
transmembrane region
potential
1378
1402
topological domain
Extracellular
potential
33
1377
topological domain
Cytoplasmic
potential
1403
2029
domain
Ig-like C2-type 1
36
128
domain
Ig-like C2-type 2
140
224
domain
Ig-like C2-type 3
234
316
domain
Fibronectin type-III 1
322
410
domain
Fibronectin type-III 2
416
508
domain
Fibronectin type-III 3
515
603
domain
Fibronectin type-III 4
610
704
domain
Fibronectin type-III 5
709
807
domain
Fibronectin type-III 6
812
904
domain
Fibronectin type-III 7
909
1002
domain
Fibronectin type-III 8
1006
1099
domain
Fibronectin type-III 9
1101
1203
domain
Tyrosine-protein phosphatase 1
1474
1729
domain
Tyrosine-protein phosphatase 2
1761
2020
modified residue
Phosphothreonine
1572
1572
glycosylation site
N-linked (GlcNAc...)
potential
176
176
glycosylation site
N-linked (GlcNAc...)
potential
253
253
glycosylation site
N-linked (GlcNAc...)
potential
298
298
glycosylation site
N-linked (GlcNAc...)
potential
553
553
glycosylation site
N-linked (GlcNAc...)
potential
616
616
glycosylation site
N-linked (GlcNAc...)
potential
666
666
glycosylation site
N-linked (GlcNAc...)
potential
721
721
glycosylation site
N-linked (GlcNAc...)
potential
774
774
glycosylation site
N-linked (GlcNAc...)
potential
915
915
glycosylation site
N-linked (GlcNAc...)
potential
962
962
glycosylation site
N-linked (GlcNAc...)
potential
1183
1183
glycosylation site
N-linked (GlcNAc...)
potential
1304
1304
active site
Phosphocysteine intermediate
by similarity
1670
1670
active site
Phosphocysteine intermediate
by similarity
1961
1961
SP Length
32
----+----1----+----2----+----3----+----4----+----5
Signal Peptide
MGLQMTAARPIAALSLLVLSLLTWTHPTIVDA
Sequence
MGLQMTAARPIAALSLLVLSLLTWTHPTIVDA
AHP
PEIIRKPQNQGVRVG
GVASFYCAARGDPPPSIVWRKNGKKVSGTQSRYTVLEQPGGISILRIEPV
RAGRDDAPYECVAENGVGDAVSADATLT
IYEGDKTPAGF
PVITQGPGTRV
IEVGHTVLMTCKAIGNPTPNIYWIK
N
QTKVDMSNPRYSLKDGFLQIENSR
EEDQGKYECVAENSMGTEHSKATN
LYVKVRRVP
PTFSRPPETISEVMLGS
NL
N
LSCIAVGSPMPHVKWMKGSEDLTPENEMPIGRNVLQLINIQESA
N
YT
CIAASTLGQIDSVSVV
KVQSL
PTAPTDVQISEVTATSVRLEWSYKGPEDL
QYYVIQYKPKNANQAFSEISGIITMYYVVRALSPYTEYEFYVIAVNNIGR
GPPSAPATCT
TGETK
MESAPRNVQVRTLSSSTMVITWEPPETPNGQVTGY
KVYYTTNSNQPEASWNSQMVDNSELTTVSELTPHAIYTVRVQAYTSMGAG
PMSTPVQV
KAQQGV
PSQPSNFRATDIGETAVTLQWTKPTHSSENIVHYEL
YW
N
DTYANQAHHKRISNSEAYTLDGLYPDTLYYIWLAARSQRGEGATTPP
IPV
RTKQYV
PGAPPR
N
ITAIATSSTTISLSWLPPPVERSNGRIIYYKVFF
VEVGREDDEATTMTL
N
MTSIVLDELKRWTEYKIWVLAGTSVGDGPRSHPI
ILRT
QEDV
PGDPQDVKATPL
N
STSIHVSWKPPLEKDRNGIIRGYHIHAQE
LRDEGKGFLNEPFKFDVVDTLEF
N
VTGLQPDTKYSIQVAALTRKGDGDRS
AAIVVKT
PGGV
PVRPTVSLKIMEREPIVSIELEWERPAQTYGELRGYRLR
WGVKDQALKEEMLSGPQMTKKRFDNLERGVEYEFRVAGSNHIGIGQETVK
IFQT
PEGT
PGGPPS
N
ITIRFQTPDVLCVTWDPPTREHRNGIITRYDVQFH
KKIDHGLGSER
N
MTLRKAVFTNLEENTEYIFRVRAYTKQGAGPFSDKLIV
ET
ERD
MGRAPMSLQAEATSEQTAEIWWEPVTSRGKLLGYKIFYTMTAVED
LDDWQTKTVGLTESADLVNLEKFAQYAVAIAARFKNGLGRLSEKVTVRI
K
PEDVPLNLRAHDVSTHSMTLSWSPPIRLTPVNYKISFDAMKVFVDSQGFS
QTQIVPKREIILKHYVKTHTINELSPFTTYNV
N
VSAIPSDYSYRPPTKIT
VTT
QMAAPQPMVKPDFYGVVNGEEILVILPQASEEYGPISHYYLVVVPED
KSNLHKIPDQFLTDDLLPGRNKPERPNAPYIAAKFPQRSIPFTFHLGSGD
DYH
N
FTNRKLEREKRYRIFVRAVVDTPQKHLYTSSPFSEFLSLDMREAPP
GERPHRPDPNWPAEPEVSVNRNKDEPE
ILWVVLPLMVSTFIVSTALIVLC
VV
KRRRQPCKTPDQAAVTRPLMAADLGAGPTPSDPVDMRRLNFQTPGMIS
HPPIPISEFANHIERLKSNDNQK
FSQEYESIEPGQQFTWDNSNLEHNKSK
NRYANVTAYDHSRVQLPAVEGVVGSDYINANYCDGYRKHNAYVATQGPLQ
ETFVDFWRMCWELKTATIVMM
T
RLEERTRIKCDQYWPTRGTETYGQIFVT
ITETQELATYSIRTFQLCRQGFNDRREIKQLQFTAWPDHGVPDHPAPFLQ
FLRRCRALTPPESGPVIVH
C
SAGVGRTGCYIVIDSMLERMKHEKIIDIYG
HVTCLRAQRNYMVQTEDQYIFIHDAILEA
IICGVTEVPARNLHTHLQKLL
ITEPGETISG
MEVEFKKLSNVKMDSSKFVTANLPCNKHKNRLVHILPYES
SRVYLTPIHGIEGSDYVNASFIDGYRYRSAYIAAQGPVQDAAEDFWRMLW
EHNSTIVVMLTKLKEMGREKCFQYWPHERSVRYQYYVVDPIAEYNMPQYK
LREFKVTDARDGSSRTVRQFQFIDWPEQGVPKSGEGFIDFIGQVHKTKEQ
FGQDGPITVH
C
SAGVGRSGVFITLSIVLERMQYEGVLDVFQTVRILRSQR
PAMVQTEDQYHFCYRAALEY
LGSFDNYTN
Original
MGLQMTAARPIAALSLLVLSLLTWTHPTIVDAAHPPEIIRKPQNQGVRVG
GVASFYCAARGDPPPSIVWRKNGKKVSGTQSRYTVLEQPGGISILRIEPV
RAGRDDAPYECVAENGVGDAVSADATLTIYEGDKTPAGFPVITQGPGTRV
IEVGHTVLMTCKAIGNPTPNIYWIKNQTKVDMSNPRYSLKDGFLQIENSR
EEDQGKYECVAENSMGTEHSKATNLYVKVRRVPPTFSRPPETISEVMLGS
NLNLSCIAVGSPMPHVKWMKGSEDLTPENEMPIGRNVLQLINIQESANYT
CIAASTLGQIDSVSVVKVQSLPTAPTDVQISEVTATSVRLEWSYKGPEDL
QYYVIQYKPKNANQAFSEISGIITMYYVVRALSPYTEYEFYVIAVNNIGR
GPPSAPATCTTGETKMESAPRNVQVRTLSSSTMVITWEPPETPNGQVTGY
KVYYTTNSNQPEASWNSQMVDNSELTTVSELTPHAIYTVRVQAYTSMGAG
PMSTPVQVKAQQGVPSQPSNFRATDIGETAVTLQWTKPTHSSENIVHYEL
YWNDTYANQAHHKRISNSEAYTLDGLYPDTLYYIWLAARSQRGEGATTPP
IPVRTKQYVPGAPPRNITAIATSSTTISLSWLPPPVERSNGRIIYYKVFF
VEVGREDDEATTMTLNMTSIVLDELKRWTEYKIWVLAGTSVGDGPRSHPI
ILRTQEDVPGDPQDVKATPLNSTSIHVSWKPPLEKDRNGIIRGYHIHAQE
LRDEGKGFLNEPFKFDVVDTLEFNVTGLQPDTKYSIQVAALTRKGDGDRS
AAIVVKTPGGVPVRPTVSLKIMEREPIVSIELEWERPAQTYGELRGYRLR
WGVKDQALKEEMLSGPQMTKKRFDNLERGVEYEFRVAGSNHIGIGQETVK
IFQTPEGTPGGPPSNITIRFQTPDVLCVTWDPPTREHRNGIITRYDVQFH
KKIDHGLGSERNMTLRKAVFTNLEENTEYIFRVRAYTKQGAGPFSDKLIV
ETERDMGRAPMSLQAEATSEQTAEIWWEPVTSRGKLLGYKIFYTMTAVED
LDDWQTKTVGLTESADLVNLEKFAQYAVAIAARFKNGLGRLSEKVTVRIK
PEDVPLNLRAHDVSTHSMTLSWSPPIRLTPVNYKISFDAMKVFVDSQGFS
QTQIVPKREIILKHYVKTHTINELSPFTTYNVNVSAIPSDYSYRPPTKIT
VTTQMAAPQPMVKPDFYGVVNGEEILVILPQASEEYGPISHYYLVVVPED
KSNLHKIPDQFLTDDLLPGRNKPERPNAPYIAAKFPQRSIPFTFHLGSGD
DYHNFTNRKLEREKRYRIFVRAVVDTPQKHLYTSSPFSEFLSLDMREAPP
GERPHRPDPNWPAEPEVSVNRNKDEPEILWVVLPLMVSTFIVSTALIVLC
VVKRRRQPCKTPDQAAVTRPLMAADLGAGPTPSDPVDMRRLNFQTPGMIS
HPPIPISEFANHIERLKSNDNQKFSQEYESIEPGQQFTWDNSNLEHNKSK
NRYANVTAYDHSRVQLPAVEGVVGSDYINANYCDGYRKHNAYVATQGPLQ
ETFVDFWRMCWELKTATIVMMTRLEERTRIKCDQYWPTRGTETYGQIFVT
ITETQELATYSIRTFQLCRQGFNDRREIKQLQFTAWPDHGVPDHPAPFLQ
FLRRCRALTPPESGPVIVHCSAGVGRTGCYIVIDSMLERMKHEKIIDIYG
HVTCLRAQRNYMVQTEDQYIFIHDAILEAIICGVTEVPARNLHTHLQKLL
ITEPGETISGMEVEFKKLSNVKMDSSKFVTANLPCNKHKNRLVHILPYES
SRVYLTPIHGIEGSDYVNASFIDGYRYRSAYIAAQGPVQDAAEDFWRMLW
EHNSTIVVMLTKLKEMGREKCFQYWPHERSVRYQYYVVDPIAEYNMPQYK
LREFKVTDARDGSSRTVRQFQFIDWPEQGVPKSGEGFIDFIGQVHKTKEQ
FGQDGPITVHCSAGVGRSGVFITLSIVLERMQYEGVLDVFQTVRILRSQR
PAMVQTEDQYHFCYRAALEYLGSFDNYTN
----+----1----+----2----+----3----+----4----+----5
Hydropathies
Home
Imprint
© 2007-2017
Dr. Katja Kapp
, Kassel &
thpr.net e. K.
, Dresden, Germany, last update 2010-06-11